Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients
- 1 June 2020
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 22 (3), e13255
- https://doi.org/10.1111/tid.13255
Abstract
Background Few data support use of 6 over 3 months of antiviral prophylaxis for cytomegalovirus (CMV) disease prevention in donor seropositive/recipient seronegative (D+R-) heart transplant recipients (HTR). Methods We retrospectively assessed CMV disease and outcomes in 310 adult HTR between July 5, 2005, and December 30, 2016, at our center. Valganciclovir (VGCV) prophylaxis was given for 3-6 months in the D+R- group. Multivariable models evaluated risk factors for CMV disease in patients who received 3 vs 6 months (+/- 1 month) of prophylaxis, with investigation of inverse probability weighting to correct for confounding variables. Results The incidence of CMV disease among all patients and the D+R- group was 8.7% (27/310) and 26.5% (22/83), respectively, and included syndrome in 22.2% (6/27) and end-organ involvement in 77.8% (21/27). In a multivariable model, 6 vs 3 months of antiviral prophylaxis was not associated with reduced risk for CMV disease (OR 2.28 [95% CI 0.66, 7.91], P = .19). CMV disease in D+R- HTR was associated with higher rates of hospitalization (87.5% [14/16] vs 6.3% [1/16], P < .001) and for a longer duration than in matched D+R- controls without disease. Conclusions Cytomegalovirus disease remains a major cause of morbidity in D+R- HTR. In contrast to documented benefit in D+R- lung and kidney recipients, VGCV duration of 6 months was not associated with a lower incidence of CMV disease in D+R- HTR compared to 3-month duration and should be reconsidered in this patient population.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (HHSN272201100041C, HHSN272201600016C, HHSN272201600019C, K23 HL143050, T32 AI118690‐03)
This publication has 33 references indexed in Scilit:
- Cytomegalovirus in Solid Organ TransplantationAmerican Journal of Transplantation, 2013
- Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patientsDrug Design, Development and Therapy, 2012
- Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trialThe Journal of Heart and Lung Transplantation, 2011
- Impact of a Preemptive Strategy After 3 Months of Valganciclovir Cytomegalovirus Prophylaxis in Kidney Transplant RecipientsTransplantation, 2011
- Preemptive Versus Sequential Prophylactic-Preemptive Treatment Regimens for Cytomegalovirus in Renal Transplantation: Comparison of Treatment Failure and Antiviral ResistanceTransplantation, 2010
- Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging studyBlood, 2008
- 24-Week Oral Ganciclovir Prophylaxis in Kidney Recipients Is Associated with Reduced Symptomatic Cytomegalovirus Disease Compared to a 12-Week CourseTransplantation, 2006
- Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2004
- Definitions of Cytomegalovirus Infection and Disease in Transplant RecipientsClinical Infectious Diseases, 2002
- Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxisTransplant Infectious Disease, 2000